References:
  1. Melrose D. Bitter pills: medicines and the third world poor Oxford, United Kingdom Oxfam, 1982.
  2. US Food and Drug Administration. Advisory Review Panel on OTC Laxative, Antidiarrheal, Emetic, and Antiemetic Drug Products. Federal Register, March 21, 1975;40:12,902–10.
  3. US Food and Drug Administration. Laxative drug products for over-the-counter human use; proposed amendment to the tentative final monograph. Federal Register, September 2, 1997;62:46,223–7.
  4. Dunnick JK, Hailey JR. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res 1996;56:4922–6.
  5. Sipe HJ Jr, Corbett JT, Mason RP. In vitro free radical metabolism of phenolphthalein by peroxidases. Drug Metab Dispos 1997;25: 468–80.
  6. Ravdin PM, van Beurden M, Jordan VC. Estrogenic effects of phenolphthalein on human breast cancer cells in vitro. Breast Cancer Res Treat 1987;9:151–4
  7. Nakamura GJ, Schneiderman LJ, Klauber MR. Colorectal cancer and bowel habits. Cancer 1984;54:1475–7.
  8. Kune GA, Kune S, Field B, Watson LF. The role of chronic constipation, diarrhea, and laxative use in the etiology of large-bowel cancer. Data from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 1988;31:507–12.
  9. Kune GA. Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study. Z Gastroenterol 1993;31:140–3.
  10. Sonnenberg A, Muller AD. Constipation and cathartics as risk factors of colorectal cancer: a meta-analysis. Pharmacology 1993;47 Suppl 1:224–33.
  11. Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 1997;57:4787–94.
  12. Jacobs EJ, White E. Constipation, laxative use, and colon cancer among middle-aged adults. Epidemiology 1998;9:385–91.
  13. Ghadirian P, Maisonneuve P, Perret C, Lacroix A, Boyle P. Epidemiology of sociodemographic characteristics, lifestyle, medical history, and colon cancer: a case–control study among French Canadians in Montreal. Cancer Detect Prev 1998;22:396–404.
  14. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. UCM 362444: 26 July 2013.
  15. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. Benefit of oral ketoconazole does not outweigh risk of liver injury in fungal infections. EMA/ 458028/2013. 26 July 2013.
  16. Patricia F. Coogan, Lynn Rosenberg, Julie R. Palmer, Brian L. Strom, Ann G. Zauber, Paul D. Stolley, Samuel Shapiro. Phenolphthalein Laxatives and Risk of Cancer. Journal of the National Cancer Institute, Vol. 92, No. 23, December 6, 2000.
  17. H. Karl Greenblatt and David J. Greenblatt. Liver Injury Associated With Ketoconazole: Review of the Published Evidence. The Journal of Clinical Pharmacology 54(12) 1321–1329